Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) shares reached a new 52-week low during trading on Tuesday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 9006 shares trading hands. The stock had previously closed at C$0.02.
Aequus Pharmaceuticals Stock Down 33.3 %
The firm has a market capitalization of C$1.33 million, a P/E ratio of -1.00 and a beta of -0.02. The firm’s 50-day moving average is C$0.02 and its 200 day moving average is C$0.02. The company has a debt-to-equity ratio of 138.88, a quick ratio of 0.46 and a current ratio of 0.07.
Aequus Pharmaceuticals (CVE:AQS – Get Free Report) last released its quarterly earnings data on Thursday, August 29th. The company reported C($0.01) earnings per share for the quarter. The firm had revenue of C$0.16 million for the quarter. As a group, equities research analysts predict that Aequus Pharmaceuticals Inc. will post -0.1 EPS for the current fiscal year.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Further Reading
- Five stocks we like better than Aequus Pharmaceuticals
- Most Volatile Stocks, What Investors Need to Know
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Dividend Payout Ratio Calculator
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- How to Choose Top Rated Stocks
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
